Table 1.

Anti-cancer activity of galangin nanoformulation in different models.

Sr.no	Nanoformulation	Experimental model	Dose	Results	Ref.
1	Galangin - gold nanoparticles(18)	SKOV3,ovarian cancer cell line, and HBL, human epithelial breast tissue	5,10, 25, 50, 100 μg/ml	Synergistic cytotoxic effect against ovarian cancer cells	30
2	Galangin loaded PEG- modified liposomes(19)	Hep G2 cells, Male Wistar rats	5 μM5 mg/kg	PEG-modified liposomes have a greater cytotoxic impact. Hep G2 cells had a 1.34-fold increase in overall apoptosis when compared to Gal-loaded unmodified liposomes.	31
3	Galangin loaded selenium nanoparticle(20)	HepG2 cells(normal human liver cell line)	10 µM	Cytotoxic effect, Induced apoptosis of cancer cells	32
4	Galangin-loaded liposomes(21)	ICR mice	300 mg/kg	Increase in oral bioavailability by 470.12% in encapsulated galanginBetter hepatoprotective effects observed compared with free galangin	33
5	Galangin loaded-NLC-RGD (loaded-Arginyl-glycyl-aspartic acid nanostructured lipid carrier) (22)	Human lung carcinoma (A549) cell line	3 mg/mL	When galangin was used in the form of GA loaded-NLC-RGD, its effects on the expression of the ABC transporter were amplified. Increased Apoptosis and Cytotoxic Effect (123.4 µM GA -NLC-RGD).	34